Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer

Journal of Molecular Medicine

Volumn 88, Issue 6, 2010, Pages 589-596

  Song, Kyo Young ^a   Wong, Joyce ^a   Gonzalez, Lorena ^a   Sheng, Gang ^a   Zamarin, Dmitriy ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Newcastle disease virus; Oncolysis; Peritoneal carcinomatosis; Stomach cancer

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER THERAPY; CARCINOMATOUS PERITONITIS; CELL KILLING; CYTOTOXICITY; DISSEMINATED CANCER; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; STOMACH CARCINOMA; STOMACH TUMOR; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASM TRANSPLANTATION; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; PERITONEAL NEOPLASMS; PERITONEUM; STOMACH NEOPLASMS;

EID: 77954565093     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-010-0605-6     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Nakajima T (2002) Gastric cancer treatment guidelines in Japan. Gastric Cancer 5:1-5
3. Park CH, Song KY, Kim SN (2008) Treatment results for gastric cancer surgery: 12 years' experience at a single institute in Korea. Eur J Surg Oncol 34:36-41
4. Okajima K, Yamada S (1986) Surgical treatment of far-advanced gastric cancer. Jpn J Cancer Clin 32:1203-1209
5. Sugarbaker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 58:96-107
6. Ajani JA, Ota DM, Jackson DE (1991) Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 67:260-265
7. Donahue JM, Mullen JT, Tanabe KK (2002) Viral oncolysis. Surg Oncol Clin N Am 11:661-680
8. Nemunaitis J (2002) Live viruses in cancer treatment. Oncol Hunt 16:1483-1492
9. Park MS, García-Sastre A, Cros JF, Basler CF, Palese P (2003) Newcastle disease virus V protein is a determinant of host range restriction. J Virol 77:9522-9532
10. Nelson NJ (1999) Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 91:1708-1710
11. Csatary LK (1971) Viruses in the treatment of cancer. Lancet 2 (7728):825
12. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A (2006) Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80:5145-5155
13. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA (1992) Newcastle disease virus selectively kills human tumor cells. J Surg Res 52:448-453
14. Sergel-Germano T, McQuain C, Morrison TG (1994) Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion. J Virol 68:7654-7658
15. Park MS, Steel J, García-Sastre A, Swayne D, Palese P (2006) Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci USA 103:8203-8208
16. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67 (17):8285-8292
17. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62 (21):6070-6079
18. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME (1994) Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54:6017-6021 (Pubitemid 24378619)
19. Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME (1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86:1228-1233 (Pubitemid 24253698)
20. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ (2001) Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172:27-36
21. Cassel WA, Murray DR (1992) A ten year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9:169-171
22. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA (1998) A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4:783-794
23. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344-1347
24. Ohtsu A (2008) Chemotherapy for metastatic gastric cancer: past, present, and future J Gastroenterol 43:256-264
25. Ceelen WP, Påhlman L, Mahteme H (2007) Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res 134:195-214
26. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M (2008) Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 98:273-276
27. Bennett JJ, Kooby DA, Delman K, McAuliffe P, Halterman MW, Federoff H, Fong Y (2000) Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 78:166-174